Liberator Medical Holdings, Inc. (OTCMKTS:LBMH) Aims for $2
A week more, and Liberator Medical Holdings, Inc. (OTCMKTS:LBMH) is still going strong, although Monday came with zero gain for the price. Still, dollar volumes reached $1.6 million, and nearly a million shares were bought up. The last few days came with growing buying volumes. LBMH now stands at $1.80. 
The behavior of LBMH is difficult to explain in the absence of a promotion, and without the boost from press releases, which have been silent for a month. But the most probable reason is the expectation for another quarterly announcement. Otherwise, LBMH burst forth after a buyback and dividend announcements. 
The bonds of LBMH with the Medicare program have been beneficial, leaving the company with:
- $7 million cash
- $6 million current liabilities
- $16 million quarterly sales, up $2 MM year-over-year
- $1.4 million quarterly net income, twofold increase year-over-year
Even without effort, LBMH started to move out of the valley toward the end of 2012, starting from below 60 cents. For a while, LBMH stalled, but the ticker is extremely responsive to positive news, and with the company logging profitable activity, the trend has support not only in investor sentiment.
With such active movement, LBMH may be taken up by promoters, as a way to boost results and add a solid company to a list of otherwise jittery selections.
In the past few days, activity spiked for several small cap companies in the biopharmaceutical and medical sectors. Selections differ by the quality of the company, with some tickers relying on preliminary research and promise, and other businesses well-established in the medical industry.
One of the climbers was Bio-Matrix Scientific Corp. (OTCMKTS:BMSN), which was more attractive for its double-zero price. Two other names, Titan Pharmaceuticals, Inc. (OTCBB:TTNP) and AP Pharma, Inc. (OTCMKTS:APPA) appear often among the most actively traded, awaiting a spike after negative comments from the FDA wiped out most of the value of the shares.
Buying resumed in early trade on Tuesday with LBMH, yet the new week will show how the trend develops, and if there will be enough positive days. While the overall picture is positive, it is best to invest in LBMH only after estimating well your potential to absorb a correction.
